A Phase I/II Study of Gemcitabine (GEMZAR)/Vinorelbine (NAVELBINE)/Liposomal Doxorubicin (DOXIL) in Relapsed/Refractory Hodgkin's Disease

Trial Information

A Phase I/II Study of Gemcitabine (GEMZAR)/Vinorelbine (NAVELBINE)/Liposomal Doxorubicin (DOXIL) in Relapsed/Refractory Hodgkin's Disease

OBJECTIVES:

- Determine the maximum tolerated dose and toxicity of gemcitabine, vinorelbine, and
doxorubicin HCl liposome in patients with relapsed or refractory Hodgkin's lymphoma.

- Determine the complete and partial response rates of patients treated with this
regimen.

OUTLINE: This is a dose-escalation, multicenter study.

Phase I:

- Patients receive vinorelbine IV over 6-10 minutes, gemcitabine IV over 30 minutes, and
doxorubicin HCl liposome IV over 30-60 minutes on days 1 and 8. Treatment continues
every 21 days for 2-6 courses in the absence of unacceptable toxicity or disease
progression. Patients who respond to treatment after 2 or more courses may stop
protocol therapy to undergo peripheral blood stem cell transplantation.

Cohorts of 3-6 patients receive escalating doses of vinorelbine, gemcitabine, and
doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is
defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience
dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to
receive treatment with gemcitabine, vinorelbine, and doxorubicin HCl liposome at the
recommended phase II dose.

Phase II:

- Patients are assigned to 1 of 2 treatment groups.

- Group 1: Patients who have not undergone prior transplantation receive
vinorelbine, gemcitabine, and doxorubicin HCl liposome as in phase I.

- Group 2: Patients who have undergone prior transplantation receive lower doses of
vinorelbine, gemcitabine, and doxorubicin HCl liposome as in group 1.

Patients are followed every 6 months for 2 years and then annually for 6 years.

PROJECTED ACCRUAL: Approximately 3-100 patients (3-42 for phase I and 20-58 for phase II [29
per group]) will be accrued for this study within 3 years.